[Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].
We report one case of hepatic encephalopathy following the administration of a somatostatin analogue (lanreotide) in a patient with a pancreatic endocrine tumor and liver metastases. Hepatic insufficiency was absent. The diagnosis of hepatic encephalopathy relied upon a positive re-challenge test, elevated veinous ammonemia, suggestive findings on electroencephalogram and lack of recurrence after lanreotide discontinuation. Encephalopathy was thought to be due to a significant decrease in hepatic blood flow caused by lanreotide; an associated thrombosis of the portal vein may have played a facilitating role.
Robin
E
E
Service de Gastroentérologie, Fédération d'Hépato-Gastroentérologie Médico-Chirurgicale de l'Hôpital Beaujon, Clichy.
Lebrec
D
D
Hammel
P
P
Bernades
P
P
Ruszniewski
P
P
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006501:Hepatic Encephalopathy / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D007273:Injections, Intramuscular; D008102:Liver Circulation; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000009:adverse effects*; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin